GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Inhibikase Therapeutics
Shares of Inhibikase, a biotech company focused on treating Parkinson's disease, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Neuro
Inhibikase Therapeutics is a biopharmaceutical company developing drugs for the treatment of Parkinson's disease and related neurodegenerative disorders. We classify it in the Neuroscience sector. The chart below illustrates the overall dynamics of this complex yet important medical segment.
Broad Market Index - GURU.Markets
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
IKT - Daily change in the company's share price Inhibikase Therapeutics
For Inhibikase Therapeutics, which works in the field of neurodegenerative diseases, daily price change is a measure of high volatility. It reflects the market's reaction to research data and is a key parameter in the biotech risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Inhibikase Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with the performance of IKT, which focuses on treating neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Inhibikase Therapeutics is a biotech company developing drugs for neurodegenerative diseases, including Parkinson's. Its shares follow the rhythm of clinical trial news, and their high volatility is part of the overall market movement where science meets finance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Inhibikase Therapeutics
Inhibikase Therapeutics' year-over-year performance is a story of drug development for neurodegenerative diseases like Parkinson's. Its 12-month market cap depends entirely on progress in clinical trials. The success of its kinase inhibitors could be a breakthrough in the treatment of these complex diseases.
Annual dynamics of market capitalization of the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biotech developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its stock price is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inhibikase is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Inhibikase Therapeutics
Inhibikase Therapeutics develops drugs to treat neurodegenerative diseases, particularly Parkinson's disease. Its monthly performance directly reflects developments in its clinical trials. Any news of progress or setbacks in the trials provokes a sharp reaction from investors.
Monthly dynamics of market capitalization of the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biotech company developing drugs for the treatment of neurodegenerative diseases, particularly Parkinson's disease. The chart below shows the overall dynamics of the biotech sector, where investors are evaluating the potential of breakthrough treatments for brain diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inhibikase Therapeutics is a biotech company developing drugs for neurodegenerative diseases such as Parkinson's. Its stock is entirely dependent on progress in clinical trials. Its volatile performance has no connection to overall market movements, reflecting only the hopes and risks of biotech.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Inhibikase Therapeutics
The weekly performance of Inhibikase, a biotech company targeting Parkinson's disease, reflects the complex journey of drug discovery for neurodegenerative diseases. Share prices react sharply to any clinical trial data that offers hope in this area.
Weekly dynamics of market capitalization of the market segment - Neuro
Inhibikase Therapeutics develops drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This is one of the most complex and risky areas in biotech. The chart will show whether the company's stock price movement is driven by its own scientific news or reflects the general optimism and pessimism in the field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Inhibikase Therapeutics is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether Inhibikase is living in its own world of clinical trials, or whether the overall market environment is influencing its stock price.
Market capitalization of the company, segment and market as a whole
IKT - Market capitalization of the company Inhibikase Therapeutics
Inhibikase's market capitalization tells the story of a biotech company developing drugs to treat neurodegenerative diseases, primarily Parkinson's disease. Its volatile price chart reflects progress in clinical trials. Its price movement reflects investors' assessment of its scientific approach and the chances of a breakthrough in this complex field.
IKT - Share of the company's market capitalization Inhibikase Therapeutics within the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, particularly Parkinson's disease. Its market capitalization reflects the potential of its scientific approach. The chart below shows how investors view its chances in this highly complex and risky area of medicine.
Market capitalization of the market segment - Neuro
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. The chart below shows the market capitalization of this complex sector. Its dynamics reflect the enormous need for effective treatments and the high risks associated with development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Inhibikase Therapeutics is a biotech company developing drugs to treat Parkinson's disease. Its market capitalization reflects the hope of a breakthrough in the treatment of this severe neurodegenerative disease. Its volatility reflects the complexity and enormous social significance of this medical problem.
Book value capitalization of the company, segment and market as a whole
IKT - Book value capitalization of the company Inhibikase Therapeutics
Inhibikase Therapeutics' balance sheet represents its capital invested in clinical trials of drugs for neurodegenerative diseases like Parkinson's. This provides a tangible, scientific foundation for combating the progressive loss of brain function. How has this risky biotech asset changed? The chart below shows its dynamics.
IKT - Share of the company's book capitalization Inhibikase Therapeutics within the market segment - Neuro
Inhibikase Therapeutics develops drugs for Parkinson's and other diseases, which requires R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its fight against neurodegeneration.
Market segment balance sheet capitalization - Neuro
Inhibikase Therapeutics develops drugs for neurodegenerative diseases. Its business is science. Its main assets are patents. The book value chart will show how "weightless" the company's financial base is for a company working on some of the most complex problems in medicine.
Book value of all companies included in the broad market index - GURU.Markets
Inhibikase Therapeutics fights Parkinson's disease and other neurodegenerative disorders. Its book value is represented by its laboratories and capital allocated for the clinical development of innovative drugs. The chart shows the resources on which the company is building its drug discovery program for these devastating conditions.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Inhibikase Therapeutics
Inhibikase's balance sheet is capital. But the market sees hope for a Parkinson's disease cure. The chart shows the "hope multiplier": the premium investors are paying for the drug's potential to change the lives of millions. This is a pure bet on scientific success.
Market to book capitalization ratio in a market segment - Neuro
Inhibikase Therapeutics develops drugs to treat neurodegenerative diseases, particularly Parkinson's disease. Its value depends on the success of its clinical programs. The chart shows the huge bet investors are making on a potential breakthrough in this complex field.
Market to book capitalization ratio for the market as a whole
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. Its assets are its research program. This chart shows the overall market valuation, but how do investors evaluate the potential of a company seeking new approaches to treating this complex disease?
Debts of the company, segment and market as a whole
IKT - Company debts Inhibikase Therapeutics
Inhibikase Therapeutics, a biotech company focused on neurodegenerative diseases, is tackling one of the most complex medical challenges. This chart shows how it is funding the extremely long and risky development of drugs for diseases like Parkinson's.
Market segment debts - Neuro
Inhibikase Therapeutics develops drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This is an extremely complex field with a high failure rate. This chart shows how the company funds its long-term, high-risk clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Inhibikase Therapeutics
Inhibikase Therapeutics is a biotech company focused on treating neurodegenerative diseases such as Parkinson's. This chart shows how reliant the company is on debt financing to advance its research and development through costly clinical trials. This indicates high risk in the pursuit of breakthroughs.
Market segment debt to market segment book capitalization - Neuro
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. This chart shows the overall debt burden in the neuroscience sector. It helps understand how the industry finances extremely risky and lengthy clinical trials.
Debt to book value of all companies in the market
Inhibikase Therapeutics is developing drugs for neurodegenerative diseases such as Parkinson's. It's a research-stage biotech company, entirely dependent on equity capital. The market's overall debt load is not directly relevant, as its risk is not the interest payments on loans, but the success of clinical trials.
P/E of the company, segment and market as a whole
P/E - Inhibikase Therapeutics
This chart for Inhibikase Therapeutics, a company developing treatments for neurodegenerative diseases such as Parkinson's, illustrates investor expectations. Its value is based not on profits, but on the enormous potential of its drugs if clinical trials are successful. It's a bet on a scientific breakthrough in a complex field of medicine.
P/E of the market segment - Neuro
Treating neurodegenerative diseases, as Inhibikase pursues, is a holy grail for biotech. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that Inhibikase is assessed as a research project with a very low chance of success, but with enormous potential if its approach to treating Parkinson's disease proves successful.
P/E of the market as a whole
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, such as Parkinson's, by inhibiting specific enzymes. This is a targeted approach. This chart, showing overall risk appetite, allows us to assess how willing investors are to fund long and complex research in one of the most challenging areas of medicine.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Inhibikase Therapeutics
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This chart illustrates the high, yet speculative, expectations surrounding its clinical programs in one of the most complex areas of medicine.
%20P%2FE%20Inhibikase%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Inhibikase-Therapeutics&v=1772649325069 "Chart of the company's future (projected) P/E Inhibikase Therapeutics")
Future (projected) P/E of the market segment - Neuro
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This chart shows profitability expectations for the neuroscience sector. It provides insight into how the market views the company's scientific approach to complex diseases and the risks of clinical development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772649325081 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This chart shows investors' risk appetite. For a company targeting one of the most complex medical challenges, it reflects the market's willingness to fund long-term, high-risk scientific projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772649325099 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Inhibikase Therapeutics
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. The financial result shown in this chart is based on clinical trial costs. It illustrates the long and risky path to developing drugs for complex diseases of the central nervous system.
Profit of companies in the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biotech company developing drugs for the treatment of neurodegenerative diseases, particularly Parkinson's disease. Its approach is aimed at inhibiting specific kinases. This graph reflects the enormous risk and potential in the field of neurology, where the development of effective therapies could lead to a multi-billion dollar market.
Overall market profit
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. Its future depends on success in clinical trials. The overall economic situation, reflected in this chart, affects the availability of capital to fund such long-term and socially significant research projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Inhibikase Therapeutics
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of Parkinson's disease and related disorders. The earnings (loss) forecast reflected here represents analysts' bets on the company's success in this complex area.
%20profit%20of%20the%20company%20Inhibikase%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Inhibikase-Therapeutics&v=1772649325182 "Graph of future (projected) profit of the company Inhibikase Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, such as Parkinson's, by inhibiting specific kinases. This chart shows revenue projections for the neuroscience sector, providing context for assessing Inhibikase's scientific approach and commercial prospects in this complex field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772649325185 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Inhibikase Therapeutics is a biotech company focused on treating neurodegenerative diseases. Its valuation is determined by the potential of its research and development. This graph, reflecting overall market sentiment, influences the availability of venture capital required to conduct lengthy and expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772649325189 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Inhibikase Therapeutics
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart reflects investor expectations for clinical success. The valuation is a bet on its scientific approach to treating these complex conditions.
P/S market segment - Neuro
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This chart shows the industry average price-to-sales ratio, reflecting investor expectations for the company's clinical trials in this complex area of medicine.
P/S of the market as a whole
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease, by inhibiting specific kinases. This chart helps understand the market's willingness to fund long-term, high-risk research in one of the most complex areas of medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Inhibikase Therapeutics
Inhibikase Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases, primarily Parkinson's disease. This chart shows its valuation relative to future projected sales. It reflects investor expectations for the success of its clinical development.
%20P%2FS%20Inhibikase%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Inhibikase-Therapeutics&v=1772649325257 "The graph of the company's future (projected) P/S Inhibikase Therapeutics")
Future (projected) P/S of the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart reflects investor expectations for the company's potential breakthrough in this complex area of medicine and its future revenue.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772649325289 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases, particularly Parkinson's disease. Its future depends on the success of clinical trials. This general expectations chart for IKT is not a direct driver. The company is working in an area with a huge unmet need.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772649325322 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Inhibikase Therapeutics
This chart illustrates the financial trajectory of a biotech company. For Inhibikase Therapeutics, which focuses on treating neurodegenerative diseases such as Parkinson's, it reflects funding from investors for clinical trials, not commercial sales revenue.
Sales of companies in the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biotech company developing drugs for the treatment of Parkinson's disease and other neurodegenerative diseases. This chart shows revenue in the neurosciences sector. Inhibikase's potential success could be a long-awaited breakthrough in the treatment of these devastating diseases and create a huge market.
Overall market sales
Inhibikase Therapeutics is a biotechnology company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. The company is working to solve one of the most complex challenges in medicine. Its scientific advances are part of the global healthcare innovation process that is shaping the economy of the future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Inhibikase Therapeutics
Inhibikase Therapeutics is a biotechnology company developing drugs for the treatment of neurodegenerative diseases, such as Parkinson's disease. Future sales projections depend on the success of its clinical programs.
%20sales%20of%20the%20company%20Inhibikase%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Inhibikase-Therapeutics&v=1772649325395 "Schedule of future (projected) sales of the company Inhibikase Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Inhibikase Therapeutics develops drugs to treat neurodegenerative diseases, particularly Parkinson's disease. The outlook for the neuroscience sector reflects a huge unmet need. The graph illustrates the high expectations for any progress in treating these complex and devastating diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772649325426 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. Its success depends on the results of clinical trials. The need for such drugs is enormous and is not dependent on economic cycles, but this timeline can impact the availability of funding for long-term research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772649325466 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Inhibikase Therapeutics
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. Being in clinical trials, it incurs high R&D costs. This chart shows the "cost of innovation"—the amount of investment in fighting these complex diseases.
Market segment marginality - Neuro
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. Its financial performance reflects its focus on clinical research. This chart provides insight into the company's operating model compared to other neuroscience companies.
Market marginality as a whole
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart shows the company's overall profit margin. Compared to this, Inhibikase is a high-risk bet on a breakthrough in a very complex area of medicine. Its future depends on clinical success.
Employees in the company, segment and market as a whole
Number of employees in the company Inhibikase Therapeutics
Inhibikase Therapeutics is a biopharmaceutical company focused on treating neurodegenerative diseases such as Parkinson's disease. Its small team of scientists and clinicians is working to advance its drugs through clinical trials. Growth on this chart will indicate key research progress and the raising of new capital.
Share of the company's employees Inhibikase Therapeutics within the market segment - Neuro
Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's disease. This chart illustrates its scientific focus. It reflects the percentage of neuroscientists and clinical researchers working on new approaches to treating these complex diseases that Inhibikase attracts.
Number of employees in the market segment - Neuro
Inhibikase Therapeutics is a biotech company focused on treating Parkinson's disease and related disorders. This chart illustrates the complex and long-term research into neurodegenerative diseases. The growth of the research team reflects the progress of clinical trials, bringing hope to millions of patients.
Number of employees in the market as a whole
Inhibikase Therapeutics is a biotech company working on the treatment of neurodegenerative diseases such as Parkinson's. Their focus is entirely on science. This general work schedule is irrelevant to them. Their future is determined solely by the results of clinical trials and regulatory decisions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Parkinson's. This chart shows how the market values its scientific potential. The high market cap per employee reflects investors' belief that a small team of scientists can create a treatment for a huge and unmet market.
%20of%20the%20company%20Inhibikase%20Therapeutics%20(IKT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Inhibikase-Therapeutics-IKT&v=1772649325614 "Chart of market capitalization per employee (in thousands of dollars) of the company Inhibikase Therapeutics (IKT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Inhibikase Therapeutics develops drugs for neurodegenerative diseases such as Parkinson's. It's a biotech company whose value is determined by scientific potential. This chart shows the enormous stake investors are placing on the company's scientific team. The high valuation per employee reflects hopes for a breakthrough drug.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772649325640 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Inhibikase Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Parkinson's. This chart reflects the employee's high valuation, as a scientific breakthrough in this complex field could lead to a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772649325645 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. It's an R&D company. This metric is negative. It reflects how much capital the company burns per scientist and doctor working to develop a cure for this complex and currently incurable disease.
%20Chart%20Inhibikase%20Therapeutics%20(IKT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Inhibikase-Therapeutics-IKT&v=1772649325654 "Company Profit Per Employee (in thousands of dollars) Chart Inhibikase Therapeutics (IKT)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Inhibikase Therapeutics (IKT) is a biotech company targeting neurodegenerative diseases such as Parkinson's. For a clinical-stage company, this graph is a theoretical benchmark. All of IKT's current operations are unprofitable and focused on research. Success would mean their team has created a drug that will generate profits above industry standards.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772649325761 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Inhibikase Therapeutics (IKT) is a biotech company targeting neurodegenerative diseases such as Parkinson's disease. It is a clinical-stage R&D company. Its negative profit per employee reflects the investment in its research team. The graph shows the "cost" of attempting to solve one of the most complex medical problems.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772649325794 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases. This chart reflects its status as a clinical-stage R&D company. Lack of revenue is normal. In the future, this metric will become a measure of the commercial success of its developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Inhibikase-Therapeutics-IKT&v=1772649325799 "Sales chart per company employee Inhibikase Therapeutics (IKT)")
Sales per employee in the market segment - Neuro
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. At the R&D stage, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee.
Sales per employee for the market as a whole
Inhibikase Therapeutics is a clinical-stage biotech company focused on treating neurodegenerative diseases such as Parkinson's. It is a 100% R&D company. This chart shows revenue per employee, which, as expected, is zero. It emphasizes that the company does not sell products but invests in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This chart shows bearish bets. Bears are betting on an extremely high risk of failure in this area. The history of clinical trials for Parkinson's drugs is littered with failures.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Inhibikase-Therapeutics-IKT&v=1772649325819 "Short Shares Chart for the Company Inhibikase Therapeutics (IKT)")
Shares shorted by market segment - Neuro
Inhibikase Therapeutics is a biotech company specializing in the treatment of neurodegenerative diseases, particularly Parkinson's disease. This chart shows the overall short positions in the biotech (neuro) sector. The high short positions in this sector reflect the market's intense skepticism due to a history of failed treatments for similar diseases.
Shares shorted by the overall market
Inhibikase (IKT) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing IKT will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics is a clinical-stage biotech. Its stock is highly sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Inhibikase-Therapeutics-IKT&v=1772649325854 "RSI 14 indicator chart for the company's stock Inhibikase Therapeutics (IKT)")
RSI 14 Market Segment - Neuro
Inhibikase (IKT) — "biotech," a "Parkinson's" "hunter." The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is IKT's growth due to its R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
For Inhibikase, a biotech company in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IKT (Inhibikase Therapeutics)
Inhibikase Therapeutics is a biotech company developing drugs for the treatment of neurodegenerative diseases, particularly Parkinson's disease. This chart shows the average analyst forecast. Their targets are based on an assessment of clinical data for their candidates and the potential for disease-modifying therapies.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IKT-Inhibikase-Therapeutics&v=1772649325878 "A chart showing analyst consensus forecasts for the expected stock price. IKT (Inhibikase Therapeutics)")
The difference between the consensus estimate and the actual stock price IKT (Inhibikase Therapeutics)
Inhibikase is a biotech company developing drugs to treat neurodegenerative diseases, primarily Parkinson's disease. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this complex but crucial R&D program.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IKT-Inhibikase-Therapeutics&v=1772649325879 "A chart showing the difference between the consensus forecast and the actual stock price. IKT (Inhibikase Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Inhibikase is a biotech company focused entirely on its R&D platform for treating Parkinson's disease. This chart reflects analysts' overall expectations for the entire neuroscience sector. It shows whether experts believe a breakthrough in neurodegenerative disease treatment is possible or whether they view the sector as an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Inhibikase Therapeutics (IKT) is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases, primarily Parkinson's disease. This chart shows the overall risk appetite, reflecting the market's willingness to fund long-term and extremely risky R&D projects in this highly complex field.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Inhibikase Therapeutics
Inhibikase Therapeutics is a clinical-stage biotech focused on neurodegeneration, primarily Parkinson's disease. They are developing drugs that target the mechanism that causes the disease. This chart is a clear indicator of faith in their (very risky) R&D. Its dynamics depend entirely on their clinical data and their chances of a breakthrough in this highly complex field.
AKIMA Market Segment Index - Neuro
Inhibikase Therapeutics is a biotech company specializing in developing drugs to treat neurodegenerative diseases, particularly Parkinson's disease. This chart shows the average index for the neurosector. It provides investors with a benchmark for how Inhibikase's performance compares to the sector average.
The AKIM Index for the overall market
Inhibikase Therapeutics is a pharmaceutical company developing protein kinase inhibitors for the treatment of Parkinson's disease and other neurodegenerations. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to the overall economic trends affecting the biotech sector.
